Ningbo Menovo Pharm Co Ltd

Menovo Pharmaceutical's shares hit the daily limit after it disclosed its 2026 half-year report. In the first half of the year, the company achieved operating revenue of 859 million yuan, up 26.79% year-on-year, and net profit attributable to the parent company of 63.6891 million yuan, up 29.83% year-on-year. In the second quarter, foreign investors including UBS Group, Morgan Stanley, and Barclays Bank became new top-ten shareholders, while Hong Kong Securities Clearing Company increased its holdings to become the second-largest shareholder. Internet-famous retail investor 'Xin Duoduo' Liu Xin became a new fourth-largest shareholder. Menovo Pharmaceutical specializes in specialty active pharmaceutical ingredients and formulations, and is one of the Chinese companies exporting the most varieties of specialty APIs to Europe.

The pharmaceutical sector rallied strongly during trading on the 6th, with weight-loss drug and innovative drug concepts standing out. Shouyao Holdings and Gan & Lee Pharmaceuticals were among multiple stocks that hit their daily limit up. As of press time, Shouyao Holdings surged by the 20 percent daily limit, Hotgen Biotech rose about 14 percent, Mabwell Bioscience, InventisBio, and Shanghai Yizhong Pharmaceutical gained over 10 percent, Gan & Lee Pharmaceuticals, Huahai Pharmaceutical, and Menovo Pharmaceutical also hit their daily limit up, BeiGene and Pharmaron climbed over 7 percent, and Hengrui Medicine advanced more than 5 percent. In the Hong Kong market, Duality Biologics, InnoCare Pharma, and Sino Biopharmaceutical rose over 10 percent, while WuXi XDC and Pharmaron gained more than 5 percent. On the news front, the National Medical Products Administration is soliciting public comments on optimizing the review and approval of cell and gene therapy drugs, encouraging clinically value-oriented R&D innovation, focusing on key areas such as malignant tumors and rare diseases, and placing eligible drugs into a 30-day review and approval pathway. Meanwhile, the overseas expansion of innovative drugs is accelerating. Since 2026, the total value of China's innovative drug license-out deals has reached 94.3 billion US dollars, up 81 percent year-on-year, with upfront payments reaching 5.5 billion US dollars, up 124 percent year-on-year, reflecting growing overseas recognition of China's innovative drug pipeline. CICC noted that leading innovative drug companies are shifting from the R&D investment phase into a positive cycle of commercial scale-up and overseas licensing revenue realization.